Biolimus A9 DEB for the Treatment of In-Stent Restenosis. 1-year outcomes of the REFORM trial

Rory Durand, Robert A. Byrne(Mater Private Hospital), Peter O’Kane(Royal Bournemouth Hospital), Giulio Stefanini(Humanitas University), Ralph Töelg(Segeberger Kliniken), Joo‐Yong Hahn(Samsung Medical Center), Bernardo Cortese, Keith Oldroyd(University of Glasgow), Jasper Trevelyan(Worcestershire Royal Hospital), Manel Sabaté(Hospital Clínico San Carlos), Marie-Claude Morice(Institut Cardiovasculaire Paris Sud), H Rai(Mater Private Hospital)
European Heart Journal
October 1, 2024
10.1093/eurheartj/ehae666.2409
Cited by 0

Related Papers

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
|PubMed|2005|2.3k
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II
|The Lancet|2013|827
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2022|566